Sept 2 (Reuters) - Biomx Inc  PHGE.A :
    * BIOMX ENTERS COLLABORATION WITH BOEHRINGER INGELHEIM WITH
THE
GOAL OF DISCOVERING MICROBIOME-BASED BIOMARKERS FOR INFLAMMATORY
BOWEL DISEASE
    * BIOMX ENTERS COLLABORATION WITH BOEHRINGER INGELHEIM WITH
GOAL
OF DISCOVERING MICROBIOME-BASED BIOMARKERS FOR INFLAMMATORY
BOWEL DISEASE
    * BIOMX - TO GENERATE METAGENOMIC DATA OF GUT MICROBIOME
SAMPLES
OBTAINED FROM IBD PATIENTS WITH AIM OF IDENTIFYING BIOMARKERS
USING XMARKER PLATFORM
    * BIOMX INC - CONTINUES TO ADVANCE WHOLLY-OWNED PHAGE
THERAPY
CANDIDATE BX002 FOR TREATMENT OF IBD WITH A PHASE 1A STUDY
EXPECTED TO BEGIN IN Q3 OF 2020
    * BIOMX INC - TERMS INCLUDE AN OPTION FOR BOEHRINGER
INGELHEIM TO
NEGOTIATE AN EXCLUSIVE RIGHT TO BIOMARKERS DISCOVERED UTILIZING
XMARKER PLATFORM

Source text for Eikon:  ID:nBw7m9PZVa 
Further company coverage:  PHGE.A 

 ((Reuters.Briefs@thomsonreuters.com;))